微小RNA-155在肝细胞癌中的表达及其对肝癌肝移植术患者预后的影响

Expression and survival prediction of microRNA-155 in hepatoceHular carcinoma after liver transplantation

目的观察微小RNA-155（miRNA-155）在肝细胞癌中的表达及其对肝癌肝移植术后肿瘤复发和患者预后的影响。方法应用定量反转录PCR检测100例肝癌样本miRNA-155表达；Kaplan—Meier和Cox比例风险回归模型分析miRNA-155对肝癌复发和预后的影响。结果肝癌肝移植术后肿瘤复发的原发肝癌45例miRNA．155表达高于55例未复发者（14．94比4．70，P=0．001）；高miRNA-155表达与肝癌微血管侵犯密切相关（P=0．001）；miRNA-155表达水平越高，患者无瘤生存期（P〈0．001）和生存期（P〈0．001）越短；Cox比例风险回归模型分析提示miRNA-155可作为肝癌肝移植术后独立的预后判断因素。结论miRNA-155在肿瘤复发的原发肝癌中过表达，可作为肝癌肝移植术预后判断的分子标志物。

Objective To explore the expression of microRNA-155 in hepatocellular carcinoma （HCC） and its contribution to recurrence and prognosis of HCC after liver transplantation （LT）. Methods The expression levels of microRNA-155 in 100 HCC samples were detected by quantitative reverse transcription-polymerase chain reaction （qRT-PCR）. Kaplan-Meier and Cox proportional regression analyses were utilized to determine the association of microRNA-155 expression with patient survivals. Results The expression levels of microRNA-155 were higher in primary HCC patients with post-LT recurrence （ n = 45, mean relative level = 14. 94 ） than those with non-recurrence （ n = 55, mean relative level = 4. 70 ） （ P = 0. 001 ） and correlated with micro-vascular invasion of HCC tissue samples （ P = 0. 001 ）. The patients with a higher expression of microRNA-155 had significantly worse recurrence-free survival （RFS： （21.5 ＋ 3.2） months, log rank P 〈 0. 001 ） and overall survival （ OS： （ 29. 3 ±3.2） months, log rank P 〈 0. 001 ） than those with a lower expression of microRNA-155 （RFS： （50. 8±3.2） months; OS： （54. 6±3.5） months）. Multivariate analysis revealed that a high expression of miR-155 was an independent prognostic predictor. Conclusion MicroRNA-155 is over-expressed in primary HCC with tumor recurrence and may serve as a novel biomarker for tumor recurrence and survival of HCC patients after LT. The detection of microRNA-155 is of clinical significance in HCC.